Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

xlomafota13 shared this article with you from Inoreader Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action Via Mol Imaging Radionucl Ther Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):107-109. doi: 10.4274/mirt.galenos.2020.69783. ABSTRACT We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime. PMID:34082512 | DOI:10.4274/mi rt.galenos.2020.69783 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.